2025-08-28 22:07:05
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Jubilant Life Sciences Ltd Q1FY21 consolidated PAT at Rs. 88.01 crore
Posted On : 2020-09-04 15:57:50( TIMEZONE : IST )
JUBILANT LIFE SCIENCES LIMITED has reported financial results for the period ended June 30, 2020.
Financial Results (Q1 FY 2020-21) - QoQ Comparison
The company has reported total income of Rs.1901.05 crores during the period ended June 30, 2020 as compared to Rs.2410.85 crores during the period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.88.01 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.260.49 crores for the period ended March 31, 2020.
The company has reported EPS of Rs.5.53 for the period ended June 30, 2020 as compared to Rs.16.35 for the period ended March 31, 2020.
| Financials | Q1 FY2020-21 | Q4 FY19-20 | % Change |
| Total Income | ₹ 1901.05 crs | ₹ 2410.85 crs |  -21.15% |
| Net Profit | ₹ 88.01 crs | ₹ 260.49 crs | -66.21% |
| EPS | ₹ 5.53 | ₹ 16.35 | -66.18% |
Financial Results (Q1 FY 2020-21) - YoY Comparison
The company has reported total income of Rs.1901.05 crores during the period ended June 30, 2020 as compared to Rs.2191.56 crores during the period ended June 30, 2019.
The company has posted net profit / (loss) of Rs.88.01 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.184.98 crores for the period ended June 30, 2019.
The company has reported EPS of Rs.5.53 for the period ended June 30, 2020 as compared to Rs.11.61 for the period ended June 30, 2019.
| Financials | Q1 FY2020-21 | Q1 FY2019-20 | % Change |
| Total Income | ₹ 1901.05 crs | ₹ 2191.56 crs | -13.26% |
| Net Profit | ₹ 88.01 crs | ₹ 184.98 crs | -52.42% |
| EPS | ₹ 5.53 | ₹ 11.61 | -52.37% |
Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, CoChairman & Managing Director, Jubilant Life Sciences said: "During the quarter, we worked diligently towards employees' safety while continuing to serve our global customers by maintaining our operations.
The company's performance in the LSI business has been better in EBITDA as well as in margins on both year-onyear as well as quarter-on-quarter due to good demand and improved pricing of select products. We maintained business continuity in all the manufacturing sites. DDDS segment witnessed year-on-year growth in revenues as well as EBITDA led by healthy demand from customers.
The Company's performance in the Pharma business had a temporary negative impact due to production suspension at our API plant. This facility has resumed operations from the month of June 2020 and since then it has been operating at a normal capacity. We are witnessing strong demand conditions and improved pricing environment. Our Radiopharma and Allergy business saw an interim decline in revenues due to postponement of elective procedures led by COVID-19 related restrictions on hospital visitations. Adverse impact in these businesses was mitigated by growth in CMO and Dosage businesses.
With the gradual opening of the US healthcare markets, demand conditions in our Radiopharma and Allergy business have started improving from second half of Q1'FY21 with substantial normalisation achieved June 2020 onwards. In our CMO business, we have entered into four separate clinical and commercial supply agreements for the GMP manufacture of novel COVID-19 treatment and vaccine candidates. Strong demand conditions in this business, along with our business development initiatives, promise upside to performance in the near term.
Overall, barring unforeseen circumstances, we expect strong performance in our Pharma, LSI and DDDS business in the remaining three quarters of FY21. During Q1'FY21, the Company reduced net debt on a constant currency basis by Rs 343 Crore."
In the first week of August 2020, the Company launched its remdesivir product in the India and other countries under the brand name 'JUBI-R'.
The Company has taken several measures to tide over the COVID-19 induced challenges. We are confident of delivering sustained growth in the medium term on back of our leadership position in various businesses and growth strategies.
Shares of JUBILANT LIFE SCIENCES LIMITED was last trading in BSE at Rs.818.7 as compared to the previous close of Rs. 794.4. The total number of shares traded during the day was 47778 in over 2999 trades.
The stock hit an intraday high of Rs. 837.3 and intraday low of 800. The net turnover during the day was Rs. 39074779.
